Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
- PMID: 32664046
- PMCID: PMC4433529
- DOI: 10.1093/annonc/mdu002
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Figures
Erratum for
-
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. Ann Oncol. 2014. PMID: 24356622 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
